Navigation Links
Cardium to Present at Southern California Investor Conference
Date:8/26/2011

SAN DIEGO, Aug. 26, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that Christopher J. Reinhard, Chairman and Chief Executive Officer, is scheduled to present at the Southern California Investor Conference on Monday, August 29, 2011, at 9:30 a.m. (Pacific) at the Island Hotel in Newport Beach, California.  The slide presentation will be available at the Company's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

About CardiumCardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium healthy lifestyle product platform.  The Company's lead product candidates include Excellagen™ topical gel for wound care management, and Generx® DNA-based angiogenic biologic for patients with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved.For Terms of Use Privacy Policy, please visit www.cardiumthx.com.Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™ and Nutra-Apps™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Announces Receipt of $1.1 Million in Funds from Philips Acquisition of Innercool Therapies
2. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
3. Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans
4. Cardium Reports on Transdel Transaction
5. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
8. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
9. Cardium to Present at OneMedForum San Francisco 2011 Conference
10. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
11. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... The global emerging cancer diagnostics market is expected to ... 2023 and reach a figure of $6.34 billion by ... disease and is affecting a huge population. Many technologies ... is focused on emerging cancer diagnostics market specifically on ... to factors such as: increasing number of cancer cases, ...
(Date:3/28/2017)... LAS VEGAS , March 28, 2017  Las ... first surgeries with XEN45 Gel Stent (Allergan, ... built up in the eye, thereby reducing intraocular pressure ... 60 million people globally are affected by glaucoma that ... in vision loss and blindness, if left untreated. ...
(Date:3/28/2017)... , March 28, 2017 The ... (dupilumab) injection to treat adults with moderate-to-severe eczema ... eczema is not controlled adequately by topical therapies, ... advisable. Dupixent can be used with or without ... demonstrates our commitment to approving new and innovative ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... ... many scientific laboratories. The assembly protocols involve many repetitive steps and often scientists ... automation, which enables the high-throughput needed, and results in a lower error rate ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (SOGO™), a specialized continuing medical education conference for clinicians who manage some of ... Square, New York. , The program will be led by co- chairs ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent ... improve teacher quality, the field must first improve teacher preparation program design. It ... the next” and that decades of input- and outcome-based research has failed to ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, ... real estate valuation industry for more than 40 years. , “Ruel is a ...
(Date:3/28/2017)... , ... March 29, 2017 , ... Dr. Isabella Wentz, ... launching a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey ... which emphasizes the fact that medication IS NOT the only solution to deal with ...
Breaking Medicine News(10 mins):